The most clinically significant recent development in feline chronic kidney disease (CKD) management is the investigation of AB070597, a novel oral agent evaluated specifically for disease modification in IRIS stage 2–3 cats. In a controlled trial, AB070597 demonstrated efficacy in managing CKD progression, with cats classified as IRIS stage 2 or 3 based on creatinine — though a notable discrepancy emerged: 71.4% of enrolled cats were simultaneously classified as IRIS stage 1 based on symmetric dimethylarginine (SDMA), underscoring ongoing uncertainty about which biomarker most accurately reflects glomerular filtration rate in clinical patients.Journal of Feli…

The reliability of SDMA as a staging biomarker has been called into question. SDMA has long been considered more sensitive than creatinine for detecting decreased glomerular filtration rate, but recent data show that the sensitivity and specificity of SDMA for detecting decreased glomerular filtration rate are comparable to those of creatinine — not superior.Journal of Feli… Until further validation is available, kidney function should be assessed using multiple biomarkers simultaneously rather than relying on any single marker.Journal of Feli…

IRIS staging itself remains the foundation of management decisions, with staging based on fasting serum creatinine and/or SDMA measured in a stable, well-hydrated patient on at least two separate occasions, and substaging based on urine protein-to-creatinine ratio assessed on at least two samples collected at least 2 weeks apart, plus systolic blood pressure measurement.Journal of Feli…

The evidence base supporting individual interventions varies considerably. Dietary phosphorus restriction via a renal diet is the most evidence-supported intervention, particularly for IRIS stages 2–4.Journal of Feli… Phosphate binders are recommended when dietary phosphorus restriction alone fails to control serum phosphate.Journal of Feli… Fluid therapy addresses dehydration and electrolyte and acid-base imbalances.Journal of Feli… Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) are indicated for sustained proteinuria and hypertension — but the evidence supporting their impact on quality of life is graded as 'poor' for proteinuria management and 'good' for hypertension management, and none of these medications has been demonstrated to increase longevity.Journal of Feli… Benazepril in proteinuric cats significantly improves appetite but not survival.Journal of Feli… Treatments for anaemia and metabolic acidosis are generally reserved for IRIS stages 3 and 4.Journal of Feli…

Owner caregiver burden has emerged as a clinically relevant management variable. In a UK survey, 99% of owners reported anxiety associated with caring for a CKD cat, with extreme worry related to prognosis reported by 72% at diagnosis and 50% at the time of survey completion; 66% reported significant changes to their daily routine.Journal of Feli… Phosphate binders were being administered by 35% of owners, antiproteinuric therapies by 25%, and natural supplements by 26%.Journal of Feli… Veterinary communication and nurse-led support are recognized as tools to reduce caregiver burden and improve long-term treatment compliance.Journal of Feli…

Probiotic therapy targeting gut dysbiosis represents an emerging investigational avenue, with multi-omics data suggesting that specific probiotic strains may influence feline CKD progression through gut microbiome and host metabolome pathways, though this remains under active investigation.Frontiers in Ve…

Would you like to go deeper on the specific IRIS staging cutoffs and substaging thresholds that should guide when to initiate each of these interventions?